Sangamo’s cell therapy receives EC orphan medicinal product designation
TX200 is developed to reduce the transplant rejection risk in HLA-A2 mismatched kidney transplant from a living donor.

TX200 is developed to reduce the transplant rejection risk in HLA-A2 mismatched kidney transplant from a living donor.
The acquisition is focused on Tazverik (tazemetostat), a first-in-class chemotherapy-free EZH2a inhibitor.
The deal will combine Alectos’ therapeutics expertise with Biogen’s development capabilities in movement disorders.
The notice says that Janssen intends to not purchase the minimum quantity of product mentioned in the initial agreement.
The latest expansion will create more than 250 new high-skilled manufacturing jobs at the company’s Kalamazoo facility.
The acceptance of NDA is based on data obtained from an open-label, multi-centre, single-arm Phase I/II study.
AT-007 also received Fast Track designation from the US FDA to treat Galactosemia.
Corbevax will be given after six months of the first two doses of either Covaxin or Covishield vaccines.
JMU will use human 3D intestinal tissue models to study the infection biology of Salmonella strains.
Thank you for subscribing to Pharmaceutical Technology